Oncolix's flagship ovarian cancer-fighting drug Prolanta has a $3 Billion market potential. Oncolix also has a worldwide patent portfolio of over 30 patents for Prolanta. Early funding for Prolanta came from the Susan G. Komen Foundation and the US government. More recent funding has been in the form of accredited investors, endowments and trusts, like the family trust of Ernest Mario. Ernest Mario served as Chief Executive Officer of Glaxo Holdings, plc, based out of London, England, known today as GlaxoSmithKline NYSE:GSK.
Ernest Mario was also the Chairman and CEO of Alza Corporation, based in Palo Alto, CA, from 1993 until the company was purchased by Johnson & Johnson, Inc, NYSE: JNJ in 2001.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.